X-Linked Disorder Characterization via Allele-Specific Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing X-linked disorders, particularly those related to X-chromosome inactivation, face challenges due to the broad and overlapping clinical phenotypes, limited availability of high-throughput expression-based methods, and the reliance on indirect DNA methylation assays that may not accurately reflect X-chromosome inactivation ratios.
Innovation Solution
An integrated high-throughput sequencing process involving whole genome, exome, and transcriptome sequencing to identify and characterize X-linked disorders by determining X-chromosome inactivation ratios through allele-specific expression analysis and phasing of heterozygous SNPs, providing a more accurate estimation of XCI ratios and identifying genomic or functional biomarkers associated with the disorder.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If HUMARA differential DNA methylation assay is used to estimate XCI ratio, then the assay is widely available and can be performed routinely, but it provides only indirect expression information from a single locus and may not accurately reflect true X-chromosome inactivation ratios
Solution Approach 1:
The patent replaces the mechanical/enzymatic methylation assay system with a molecular biology system based on next-generation sequencing and bioinformatic analysis. This substitution enables direct measurement of allele-specific expression across the entire X chromosome, dramatically improving measurement precision while maintaining routine applicability through high-throughput sequencing technologies.
Solution Approach 2:
The patent employs whole-exome sequencing and RNA-seq data that serve multiple functions: they identify pathogenic variants, determine allele-specific expression, and calculate XCI ratios simultaneously. This multi-functional approach provides comprehensive diagnostic information from a single sequencing experiment, improving both accuracy and efficiency.
2Measurement precision
If whole-exome sequencing and RNA-seq are integrated to determine XCI ratios, then diagnostic accuracy and functional characterization improve, but the complexity of the sequencing and analysis process increases
Solution Approach 1:
The patent merges whole-exome sequencing and RNA-seq workflows into an integrated diagnostic pipeline. By combining DNA and RNA analysis from the same patient samples, the method simultaneously identifies pathogenic variants and characterizes their functional impact on X-chromosome inactivation, improving diagnostic accuracy while streamlining the overall process through shared library preparation and sequencing steps.
Solution Approach 2:
The patent introduces bioinformatic pipelines as intermediaries that automatically process and integrate data from both sequencing modalities. These computational tools align reads, call variants, quantify allele-specific expression, and calculate XCI ratios, thereby managing the analytical complexity without increasing wet-lab procedural complexity.
3Measurement precision
If allele-specific expression analysis is performed across multiple X-linked genes, then the precision of XCI ratio estimation improves, but the computational resources and analysis time required increase
Solution Approach 1:
The patent performs preliminary actions by pre-processing RNA-seq data during the standard workflow, including alignment to the reference genome, identification of heterozygous SNPs, and quantification of allele-specific reads. By completing these computational steps as part of the routine sequencing pipeline rather than as separate post-hoc analyses, the method minimizes additional analysis time while maintaining high precision in XCI ratio estimation.
Data Source
AI summary
The present invention relates to processes for characterizing and screening for the existence or predisposition to X-linked disorders associated with changes in X-chromosome inactivation. The present invention also relates to processes of reducing a disease phenotype associated with an X-linked disorder in a female subject.